DeepMed Research

Ferring Pharmaceuticals, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ferringusa.com

Clinical Trials

Pharmacokinetics and Safety of the 100 Mcg Misoprostol Vaginal Insert (MVI 100)

Phase 2

Withdrawn

Conditions: Cervical Ripening
Induction of Labor

Interventions: Drug: Misoprostol Vaginal Insert (MVI 100)

First Posted Date: 2007-09-12

Last Posted Date: 2012-06-18

Lead Sponsor: Ferring Pharmaceuticals

Registration Number: NCT00528255

Locations: 🇺🇸
Long Beach Memorial Hospital, Long Beach, California, United States
🇺🇸
Paradise Valley Hospital, Phoenix, Arizona, United States
🇺🇸
Santa Clara Valley Medical Center, San Jose, California, United States

and more 3 locations

Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.

Phase 2

Completed

Conditions: BPH

Interventions: Drug: Degarelix

First Posted Date: 2007-09-11

Last Posted Date: 2015-05-04

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT00527488

Locations: 🇩🇪
CRS Clinical Research Services Monchengladback GmbH, Monchengladbach, Germany

Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia

Phase 3

Completed

Conditions: Nocturia

Interventions: Drug: Placebo
Drug: desmopressin acetate

First Posted Date: 2007-05-23

Last Posted Date: 2015-11-01

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 799

Registration Number: NCT00477490

Locations: 🇺🇸
PharmQuest, Greensboro, North Carolina, United States
🇺🇸
Advanced Research Associates, Corpus Christi, Texas, United States
🇺🇸
Accelovance, Houston, Texas, United States

and more 69 locations

Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix

First Posted Date: 2007-05-02

Last Posted Date: 2011-03-23

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 133

Registration Number: NCT00468286

Locations: 🇺🇸
Regional Urology, Shreveport, Louisiana, United States
🇺🇸
The Urology Center, Greensboro, North Carolina, United States
🇺🇸
State College Urologic Association, State College, Pennsylvania, United States

and more 23 locations

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix 160 mg / Degarelix 160 mg
Drug: Leuprolide 7.5 mg / Degarelix 160 mg
Drug: Degarelix 80 mg / Degarelix 80 mg
Drug: Leuprolide 7.5 mg / Degarelix 80 mg

First Posted Date: 2007-03-26

Last Posted Date: 2013-03-21

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 386

Registration Number: NCT00451958

Locations: 🇺🇸
South Orange County Medical Research Center, Laguna Hills, California, United States
🇺🇸
Seattle Urology Research Center, Burien, Washington, United States
🇺🇸
Urology Associates Research, Englewood, Colorado, United States

and more 51 locations

Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix

Phase 2

Completed

Conditions: Infertility, Female

Interventions: Drug: Degarelix mid-luteal, 2.5 mg
Drug: Placebo

First Posted Date: 2007-02-12

Last Posted Date: 2011-06-02

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 85

Registration Number: NCT00434122

Locations: 🇪🇸
IVI-Madrid, Madrid, Spain
🇨🇿
ISCARE IVF a.s., Prague, Czech Republic
🇪🇸
IVI-Valencia, Valencia, Spain

and more 1 locations

Double-Blind,Randomized,Placebo-Controlled Efficacy & Safety Study of EUFLEXXA™ for Treatment of OA of the First CMC

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Device: sodium hyaluronate
Device: placebo

First Posted Date: 2007-01-18

Last Posted Date: 2011-05-19

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 79

Registration Number: NCT00423371

Locations: 🇺🇸
All Florida Orthopedic Association, St. Petersburg, Florida, United States

Efficacy and Safety of XP12B in Women With Menorrhagia

Phase 3

Completed

Conditions: Heavy Menstrual Bleeding
Menorrhagia

Interventions: Drug: Tranexamic acid tablets
Drug: Placebo tablets

First Posted Date: 2006-11-20

Last Posted Date: 2015-05-13

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 304

Registration Number: NCT00401193

Locations: 🇺🇸
Investigative Site, Renton, Washington, United States

Efficacy and Safety Study of XP12B in Women With Menorrhagia

Phase 3

Completed

Conditions: Menorrhagia
Heavy Menstrual Bleeding

Interventions: Drug: Placebo tablets
Drug: Tranexamic acid tablets

First Posted Date: 2006-10-11

Last Posted Date: 2011-05-04

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 196

Registration Number: NCT00386308

Locations: 🇺🇸
Investigative Site, Menomonee Falls, Wisconsin, United States

A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee

Not Applicable

Completed

Conditions: Osteoarthritis, Knee

Interventions: Device: EUFLEXXA™
Device: placebo

First Posted Date: 2006-09-21

Last Posted Date: 2011-12-28

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 588

Registration Number: NCT00379236

Locations: 🇺🇸
Investigational site, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy